Pexidartinib was also combined with other anti-tumor drugs like PD-1 checkpoint to approach a better outcome, in Esophageal adenocarcinoma rat model, the use of pexidartinib can improve the efficacy of PD-1 immune checkpoint, Endpoint tissue gene expression results showed that transcription levels of both TGFβ and Arg1 were significantly decreased, which was consistent with our results (Omstead et al., 2022). Here, TGFB1 is linked to esophageal adenocarcinoma.